Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

Trump Announces Pfizer Deal He Says Will Lower Certain Drug Prices

The Trump administration on Tuesday announced a deal granting Pfizer a three-year reprieve on planned tariffs as the pharmaceutical giant vowed to voluntarily lower the prices of unspecified drugs for US purchase.

International Business Times

Pfizer Becomes First Drugmaker To Join Trump's Price Cut Push

On Tuesday, Pfizer Inc. (NYSE:PFE) announced a historic agreement with the Trump Administration to ensure U.S. patients pay lower prices for their prescription medicines.

Benzinga

AnaptysBio Charts Path To Split Into Two Public Companies By 2026

AnaptysBio, Inc. (NASDAQ:ANAB) announced on Tuesday that it plans to explore separating its business into two independent, publicly traded companies.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer agrees to offer discounted drugs through new federal website, Trump announces

President also said that company would offer medications to Medicaid at ‘most favored nation’ pricing

The Guardian - US

Pfizer agrees to lower prescription drug costs for Medicaid in a deal with Trump

Drugmaker Pfizer has agreed to lower drug costs and invest $70 billion in U.S. manufacturing under a deal struck with President Donald Trump's administration

The Independent UK

Michelle Mone accuses UK Government of 'scapegoating' over PPE firm

Tory peer Michelle Mone accused the UK Government of making her and her husband a 'poster couple for the PPE scandal' ...

The National (Scotland)

Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown

Thermo Fisher Scientific Inc. (NYSE:TMO) is tapping the U.S. investment-grade bond market with a four-part, dollar-denominated offering, as companies move to secure funding ahead of a potential U.S. government shutdown.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Pharma's Direct-To-Patient Wave Hits Novartis Next

The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine.

Benzinga

Emma Walmsley steadied GSK – but doubts linger over growth targets

The outgoing chief executive reshaped the drugmaker, yet scepticism persists over promised revenues

The Guardian - UK

AstraZeneca’s listing rejig spells long-term danger for London

It’s not skipping off entirely to New York, but pharma giant sets a worrying precedent for UK stock market

The Guardian - UK

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk

The U.S. pharmaceutical industry is at the center of a policy maelstrom. President Donald Trump on Sep 25, put a 100% tariff on imported branded and patented medicines starting from Oct 1 with threats that tariffs might go up to as much as 250% in future. The instant market impact…

Benzinga

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of approximately $8 billion.

Benzinga

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.

Benzinga

The abortion pill is safe. But why should Trump let facts get in the way?

RFK Jr is conducting a review of mifepristone, citing a deeply flawed study. The move could be devastating for women

The Guardian - US

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Emma Walmsley steps down as CEO of GSK as pharmaceutical industry faces upheaval

The drug and vaccine maker is a £60bn firm – one of the biggest in the UK

International Business Times

GSK Switches CEO As Trump Tariffs Test Pharma

British pharmaceutical giant GSK on Monday said longtime chief executive Emma Walmsley will be replaced by its chief commercial officer in January, as the company navigates US tariffs on the sector.

The Guardian - UK

AstraZeneca to upgrade US listing in ‘knock-back for London’

UK’s biggest drugmaker will put its US shares on a par with its London-based stock but says HQ will stay in Cambridge

Benzinga

Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms

President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

GSK’s Emma Walmsley to step down as chief executive after eight years

Chief commercial officer Luke Miels to take over as CEO at Britain’s second-biggest drugmaker

The Guardian - UK

Pfizer sued in US over contraceptive that women say caused brain tumours

US class action lawsuit alleges company failed to warn about risks of using contraceptive injection Depo-Provera

Axios

Trump's epic economic and drug figures fizzle under scrutiny

Trump's claims on tariff revenue and decreasing drug prices clash with expert data.

The Independent UK

NHS facing ‘critical threat’ after Trump pressure to hike drug prices

NEWS ANALYSIS: Drug prices in the UK could rise amid 100 per cent tariffs on branded medicines and pressure from US President Donald Trump to stop ‘global freeloading’, Alicja Hagopian reports

International Business Times

The Nations And Firms Threatened By Trump's Pharma Tariffs

Donald Trump has shocked the global drug industry by announcing 100-percent tariffs on all branded, imported pharmaceutical products -- unless companies are building manufacturing plants in the United States.

Benzinga

Trump's 100% Drug Tariffs 'A Meaningful Commercial Hit' For Americans, But 'Loopholes' Could Blunt Impact, Says Analyst

President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly Big Pharma, remains displeased.

Radio France Internationale

Calls for Covid vaccine boycott spur tensions in French pharmacy sector

As French pharmacists call for a boycott of Covid-19 vaccine orders, professional bodies and unions have issued stern warnings over the threat to public health.

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.